Kestra Medical Technologies Ltd. (KMTS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, KMTS scores 50 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield -6.4%), Whale 13F Flow 16/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 9/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 14/20 (Altman Z 9.65; Piotroski F 5/9; Debt/Equity 0.15).

The weakest pillars are the cash engine and insider conviction, which together point to the central tradeoff: the company is consuming cash rather than generating it, and insider-flow signals are unsupportive. The strongest pillar is institutional positioning, which indicates that large holders have been net accumulating or positioning through options, even though insider activity is weak. The balance sheet scores moderately well on the forensic measures, with a high Altman Z and low Debt/Equity, which suggests near-term solvency is not the primary concern. The main upside driver a prospective investor would weigh is the possibility that revenue growth converts into cash generation; the main valuation tradeoff is that the stock trades at a $1.82B market cap while reported operating and net margins are deeply negative and FCF yield is negative. Investors evaluating the stock today would need to judge whether the institutional flow signal outweighs the weak fundamental and insider readings.

Per the SEC financials, revenue rose from $27.8M in FY 2023 to $95.1M in FY 2025, while operating and net losses widened over the same span. The source data reports a gross margin of 51.4%, an operating margin of -60%, and a net margin of -60%, with ROIC at -35%. The Altman Z-Score is 9.65 and the Piotroski F-Score is 5 out of 9, per the Roarable RQD rating. Balance sheet posture shows cash of $291.3M against debt of $42.3M and a Debt/Equity ratio of 0.15 in the forensic pillar data.

Per the recent news wire, the most prominent item is a report that an insider sold shares worth $443,389 according to a recent SEC filing, which appears across several outlets. Other items include a report of three Kestra presentations scheduled for November and December with live webcasts and replays, a Simply Wall St valuation-focus piece questioning whether the stock is fully valued, and a MarketBeat report noting a 9.8% share price climb. All news items are tagged with a YELLOW light and MARKET WIRE impact label. Risk watch items include the insider sale disclosure and the valuation debate. No proprietary signals are present in the Butterfly graph.

• What drove the step-up in FY 2025 revenue to $95.1M, and is it recurring?
• What is the path from negative FCF of $-116.6M to positive cash generation, and on what timeline?
• Does the $291.3M cash balance fund operations through the period of sustained losses?
• What are the identities and holdings of the institutional holders behind the accumulation signal?
• What is the context and scale of the insider sale and any Congressional trades?